Geoffrey A. Holdgate
AstraZeneca (United Kingdom)(GB)AstraZeneca (Singapore)(SG)
Publications by Year
Research Areas
Computational Drug Discovery Methods, thermodynamics and calorimetric analyses, Ubiquitin and proteasome pathways, Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.(2001)415 cited
- → Epidermal growth factor receptor tyrosine kinase(1994)261 cited
- → Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530(2009)254 cited
- → Mechanistic enzymology in drug discovery: a fresh perspective(2017)213 cited
- → The Entropic Penalty of Ordered Water Accounts for Weaker Binding of the Antibiotic Novobiocin to a Resistant Mutant of DNA Gyrase: A Thermodynamic and Crystallographic Study(1997)206 cited
- → Measurements of binding thermodynamics in drug discovery(2005)205 cited